PRECIGEN, INC.

We are a commercial-stage biopharmaceutical company focused on developing precision medicines. We use our proprietary technology platforms to create product candidates for urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Our technology platforms support the construction of gene programs for efficacy, delivery through viral, non-viral, and microbe-based methods for lower costs, and gene expression control for safety. Our therapeutic platforms, including AdenoVerse immunotherapy and UltraCAR-T, allow us to control gene expression and modify biological molecules to treat underlying disease conditions. We have also developed UltraPorator, a proprietary electroporation device, for rapid and cost-effective manufacturing of UltraCAR-T therapies. In August 2025, the FDA fully approved our product, Papzimeos (zopapogene imadenovec-drba, PRGN-2012), for adults with recurrent respiratory papillomatosis (RRP). RRP is a rare disease caused by chronic human papillomavirus (HPV) 6 or HPV 11 infection. Papzimeos is a non-replicating adenoviral vector-based immunotherapy designed to express a fusion antigen of HPV types 6 and 11 proteins, aiming to generate an immune response against these proteins in RRP patients. Our clinical pipeline includes PRGN-2009, based on our AdenoVerse immunotherapy platform, and PRGN-3005, PRGN-3006, and PRGN-3007, built on our UltraCAR-T platform.